Detail akcie Beta Bionics Rg online

Business Summary: Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Beta Bionics Inc revenues increased 52% to $68.1M. Net loss increased 63% to $59.7M. Revenues reflect PBP channel - Single-use products segment increase from $2.1M to $13.8M, DME channel - Single-use products segment increase from $7.7M to $16.3M. Higher net loss reflects Sales and marketing - Balancing value increase of 66% to $41.7M (expense).